Search

Your search keyword '"Aussedat, Guillaume"' showing total 14 results
Start Over Author "Aussedat, Guillaume"
14 results on '"Aussedat, Guillaume"'

1. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Bourbon, Estelle, Sesques, Pierre, Gossez, Morgane, Tordo, Jérémie, Ferrant, Emmanuelle, Safar, Violaine, Wallet, Florent, Aussedat, Guillaume, Maarek, Alizée, Bouafia, Fadhela, Karlin, Lionel, Ghergus, Dana, Golfier, Camille, Lequeu, Hélène, Lazareth, Anne, Schwiertz, Vérane, Viel, Sébastien, Idlhaj, Maryam, Ghesquières, Hervé, Monneret, Guillaume, Bachy, Emmanuel, and Venet, Fabienne

Published
2023
Full Text
View/download PDF

2. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.

Author

Sesques, Pierre, Karlin, Lionel, Massy, Emmanuel, Maarek, Alizée, Aussedat, Guillaume, Lazareth, Anne, Golfier, Camille, Bouafia-Sauvy, Fadhela, Lequeu, Helene, Ghergus, Dana, Safar, Violaine, Ferrant, Emmanuelle, Bachy, Emmanuel, Ghesquières, Hervé, Confavreux, Cyrille B., Demangel, Delphine, Perrial, Emeline, and Dumontet, Charles

Subjects
TIME of death, MULTIPLE myeloma, DISEASE progression, CAUSES of death, KIDNEY failure
Abstract

Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel therapies, little attention has been paid to latter stages of patient follow-up. Patients and methods: In order to describe patient management during this critical period as well as the immediate causes and circumstances of death, we have analyzed a single center series of 100 patients diagnosed with myeloma who died between 2016 and 2021. Results: Patients received a median of 3 lines of treatment, including 2 during their last year of life. Sixty per cent of patients had received daratumumab. Fifty patients had obtained complete remission or very good partial response at some time during the course of disease but 75 were refractory to the last treatment line. Eighteen patients died while their disease was stable or in remission while 77 had confirmed progressive disease at time of death. Thirty six patients had uncontrolled sepsis, 49 were in renal failure and 24 had hypercalcemia at the time of death. Seventy three patients presented with lymphopenia. Disease progression was documented in a majority of MM patients at the time of death and was associated with disease-related complications in a significant number of patients. Conclusion: Disease progression remains the main cause of death in patients with multiple myeloma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.

Author

Lan, Caroline Le, Belot, Aurélien, Golfier, Camille, Audin, Bérénice, Sesques, Pierre, Bernier, Adeline, Safar, Violaine, Ferrant, Emmanuelle, Lazareth, Anne, Lequeu, Hélène, Karlin, Lionel, Ghergus, Dana, Maarek, Alizée, Aussedat, Guillaume, Idlhaj, Maryam, Salles, Gilles, Cherblanc, Fanny, Bachy, Emmanuel, and Ghesquieres, Hervé

Subjects
TEACHING hospitals, HIV infections
Abstract

The article discusses the evaluation of participation and recruitment bias in a real-world data (RWD) study called REALYSA, which focuses on newly diagnosed lymphoma patients. The study found that 54% of patients were included in the program, and factors such as age, gender, lymphoma subtype, performance status, and comorbidities were analyzed. The findings provide insights into patient participation in RWD programs and contribute to the understanding of lymphoma treatment strategies. The study also found that certain factors, such as disease aggressiveness and management approach, influenced the inclusion rate in the program. However, the study had limitations and further research is needed to better understand selection bias in real-world lymphoma cohorts. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. Evaluation of Participation and Recruitment Bias in a Prospective Real-Life Multicentric Cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for Newly Diagnosed Lymphoma Patients over One Year in a Hematology Department of Teaching Hospital

Author

LE Lan, Caroline, primary, Belot, Aurelien, additional, Golfier, Camille, additional, Audin, Berenice, additional, Sesques, Pierre, additional, Bernier, Adeline, additional, Safar, Violaine, additional, Marquet, Alexandra, additional, Ferrant, Emmanuelle, additional, Lazareth, Anne, additional, Lequeu, Helene, additional, Bouafia, Fadhela, additional, Karlin, Lionel, additional, Ghergus, Dana, additional, Maarek, Alizee, additional, Aussedat, Guillaume, additional, Idlhaj, Maryam, additional, Salles, Gilles, additional, Cherblanc, Fanny, additional, Bachy, Emmanuel, additional, and Ghesquieres, Herve, additional

Published
2022
Full Text
View/download PDF

5. Outcome in Multiple Myeloma Patients Treated in the Era of Modern Therapies Who Were Admitted to Intensive Care: A Retrospective Analysis from a Teaching Hospital between 2014 and 2019

Author

Gross, Zofia, primary, Idlhaj, Maryam, additional, Karlin, Lionel, additional, Friggeri, Arnaud, additional, Lazareth, Anne, additional, Golfier, Camille, additional, Lequeu, Helene, additional, Bouafia Sauvy, Fadhela, additional, Sesques, Pierre, additional, Safar, Violaine, additional, Ferrant, Emmanuelle, additional, Ghergus, Dana, additional, Maarek, Alizee, additional, Aussedat, Guillaume, additional, Salles, Gilles, additional, Bachy, Emmanuel, additional, Wallet, Florent, additional, and Ghesquieres, Herve, additional

Published
2022
Full Text
View/download PDF

6. Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study

Author

Aussedat, Guillaume, primary, Maucort-Boulch, Delphine, additional, Rey, Philippe, additional, Safar, Violaine, additional, Karlin, Lionel, additional, Elsensohn, Mad Helenie, additional, Bachy, Emmanuel, additional, Lebras, Laure, additional, Favier, Bertrand, additional, Vantard, Nicolas, additional, Ghergus, Dana, additional, Golfier, Camille, additional, Sesques, Pierre, additional, Lazareth, Anne, additional, Lequeu, Hélène, additional, Ferrant, Emmanuelle, additional, Salles, Gilles, additional, Nicolas-Virelizier, Emmanuelle, additional, and Ghesquieres, Hervé, additional

Published
2021
Full Text
View/download PDF

7. Skeletal Muscle Index, As a Measure of Muscle Mass, Is a Significant Prognostic Factor for Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma Patients

Author

Antherieu, Gabriel, Julia, Edith, Maarek, Alizee, Safar, Violaine, Ferrant, Emmanuelle, Traverse-Glehen, Alexandra, Lazareth, Anne, Lequeu, Helene, Cordeil, Stéphanie, Aussedat, Guillaume, Golfier, Camille, Ghergus, Dana, Sesques, Pierre, Karlin, Lionel, Bouafia Sauvy, Fadhela, Salles, Gilles, Bachy, Emmanuel, Jouanneau, Emmanuel, Ducray, Francois, Boussel, Loic, and Ghesquieres, Herve

Published
2023
Full Text
View/download PDF

8. PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers

Author

Aussedat, Guillaume, primary, Idlhaj, Maryam, additional, Durand, Amandine, additional, Roussel, Xavier, additional, Brice, Pauline, additional, Salles, Gilles, additional, Deau Fischer, Benedicte, additional, Chauchet, Adrien, additional, Rossi, Cedric, additional, and Ghesquieres, Herve, additional

Published
2020
Full Text
View/download PDF

9. Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.

Author

Aussedat, Guillaume, Maucort-Boulch, Delphine, Rey, Philippe, Safar, Violaine, Karlin, Lionel, Elsensohn, Mad Helenie, Bachy, Emmanuel, Lebras, Laure, Favier, Bertrand, Vantard, Nicolas, Ghergus, Dana, Golfier, Camille, Sesques, Pierre, Lazareth, Anne, Lequeu, Hélène, Ferrant, Emmanuelle, Salles, Gilles, Nicolas-Virelizier, Emmanuelle, and Ghesquieres, Hervé

Subjects
*DIFFUSE large B-cell lymphomas, *IFOSFAMIDE, *RITUXIMAB, *STEM cell transplantation, *ETOPOSIDE
Abstract

We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m2) in combination with etoposide (300 mg/m2) and ifosfamide (1500 mg/m2) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64–92). The median number of previous line was 1 (range 1–8). Patients received a median of six cycles (1–12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3–4 neutropenia (19%), 7 a grade 3–4 thrombocytopenia (10%) without grade 3–4 non-hematological toxicity. With a median follow up of 7.8 months, the median progression-free survival, overall survival, and duration of response were 4.4 months, 9.4 months, and 12 months, respectively. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases

Author

Aussedat, Guillaume, primary, Traverse‐Glehen, Alexandra, additional, Stamatoullas, Aspasia, additional, Molina, Thierry, additional, Safar, Violaine, additional, Laurent, Camille, additional, Michot, Jean‐Marie, additional, Hirsch, Pierre, additional, Nicolas‐Virelizier, Emmanuelle, additional, Lamure, Sylvain, additional, Regny, Caroline, additional, Picquenot, Jean‐Michel, additional, Ledoux‐Pilon, Albane, additional, Tas, Patrick, additional, Chassagne‐Clément, Catherine, additional, Manson, Guillaume, additional, Lemal, Richard, additional, Fontaine, Juliette, additional, Le Cann, Marie, additional, Salles, Gilles, additional, Ghesquières, Hervé, additional, Copie‐Bergman, Christiane, additional, and Sarkozy, Clémentine, additional

Published
2020
Full Text
View/download PDF

13. Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Author

Aussedat, Guillaume, primary, Maucort-Boulch, Delphine, additional, Rey, Philippe, additional, Safar, Violaine, additional, Karlin, Lionel, additional, Elsensohn, Mad-Helenie, additional, Lebras, Laure, additional, Sarkozy, Clementine, additional, Bachy, Emmanuel, additional, Favier, Bertrand, additional, Vantard, Nicolas, additional, Sesques, Pierre, additional, Lazareth, Anne, additional, Ferrant, Emmanuelle, additional, Ghergus, Dana, additional, Salles, Gilles, additional, Nicolas-Virelizier, Emmanuelle, additional, and Ghesquieres, Herve, additional

Published
2018
Full Text
View/download PDF

14. Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Author

Aussedat, Guillaume, Ghesquières, Hervé, Stamatoullas, Aspasia, Hirsch, Pierre, Nicolas-Virelizier, Emmanuelle, Cartron, Guillaume, Regny, Caroline, Karlin, Lionel, Chassagne-Clément, Catherine, Safar, Violaine, Albin, Nicolas, Deleuze, Antoine, Lambour, Alexis, Daguindau, Nicolas, Copie, Christiane, Lemal, Richard, Salles, Gilles, traverse-Glehen, Alexandra, and Sarkozy, Clementine

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results